NexGard SPECTRA chewable tablets

NexGard SPECTRA is a highly recognized veterinary medicinal product used to treat and prevent flea, tick, and worm infestations in dogs. The product was originally developed by Merial, a leading animal health company based in France. Merial was a pioneer in developing the active ingredient afoxolaner, which serves as the core of the NexGard product line.

The manufacturing of NexGard SPECTRA for the global market is centered largely in France, particularly at facilities in Toulouse and Lyon, where the batch release and production under pharmaceutical standards occur. However, depending on regional distribution and local regulatory requirements, production may involve specialized facilities in other countries.

In terms of ownership, the brand underwent a significant transition when Boehringer Ingelheim, a German family-owned pharmaceutical giant, acquired Merial from Sanofi in 2017. As of 2024 and looking toward 2026, Boehringer Ingelheim remains the ultimate owner and global distributor of the NexGard range, solidifying its position as one of the largest players in the international animal health market.